Endovascular Engineering Collects $80 Million in Funding

Endovascular Engineering Inc. (E2) has completed an oversubscribed $80 million Series C financing co-led by Gilde Healthcare and Norwest. Additional monetary support came from Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, M&L Healthcare Investments, two existing but undisclosed strategic investors, and a new global strategic backer.

The new financing will help support commercialization of E2’s Hēlo Thrombectomy Platform for pulmonary embolism treatment, the third leading cause of cardiovascular death.

“This is a pivotal milestone for E2 as we continue our mission to improve options for patients and physicians in the VTE space,” E2 CEO Dan Rose said. “We are proud of the capabilities of the Hēlo Platform, and this financing enables us to build a strong commercial organization while continuing important investments in R&D and Operations.”

The Hēlo Platform addresses the limitations of legacy systems and features a patented dual-action mechanism that integrates aspiration with mechanical clot disruption. The system delivers large-bore performance through a small-profile catheter, enabling efficient single-pass procedures. E2’s integrated platform supports procedural efficiency and clinical performance as adoption of mechanical thrombectomy continues to expand.

“Pulmonary embolism is a complex and often life-threatening condition, and there remains a need for more effective procedural solutions,” Norwest General Partner Zack Scott, M.D., commented. “We are impressed by E2’s leadership team and their approach to building a scalable commercial organization. E2’s technology will become the platform of choice for treating pulmonary embolism with mechanical thrombectomy, and we look forward to supporting their next phase of growth.”

This investment marks Gilde’s return to the venous thromboembolism (VTE) category, having previously led Inari Medical’s Series C commercial financing and remained a key investor until its successful acquisition by Stryker. E2 bigwigs claim Glide’s financial support reflects a strong conviction in E2’s differentiated approach and the Hēlo platform’s potential to shape the next generation of thrombectomy technology.

“E2 represents the type of innovation we look for—technology that meaningfully advances clinical care and has the potential to define a category,” Glide Healthcare General Partner Geoff Pardo stated. “We believe the Hēlo Platform addresses unmet needs in thrombectomy and are excited to support E2 as they scale toward commercialization and broader clinical impact.”

Both Scott and Pardo will join the E2 Board.

The Hēlo Thrombectomy System non-surgically removes emboli and thrombi from pulmonary arteries and venous vasculature. The system allows for the injection, infusion, and/or aspiration of contrast media and other fluids into or from blood vessels.

Endovascular Engineering Inc. is a commercial-stage medical technology company advancing VTE treatment. The Menlo Park, Calif.-based company is developing and deploying solutions to improve clinical outcomes and procedural efficiency in clot removal, aimed at addressing the complex challenges in VTE intervention.